References

1. Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, Dippel A, Oganesyan V, van Dyk N, Chen X, Cantu E et al.. (2024) AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci Transl Med, 16 (753): eado2817. [PMID:38924429]

2. Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM et al.. (2025) Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis, [Epub ahead of print]. [PMID:40015292]

3. Loubet P, Gaborit B, Salpin M, Gardeney H, Benotmane I, Systchenko T. (2024) Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France. Hum Vaccin Immunother, 20 (1): 2387221. [PMID:39143811]

4. Zhu F, Rajan S, Hayes CF, Kwong KY, Goncalves AR, Zemla AT, Lau EY, Zhang Y, Cai Y, Goforth JW et al.. (2025) Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape. Sci Adv, 11 (13): eadu0718. [PMID:40153503]